Ra Pharmaceuticals Inc.
Developing oral peptide-like drugs using synthetic amino acids
This article was originally published in Start Up
Executive Summary
Ra Pharmaceuticals Inc. is developing and establishing a new class of drugs called Cyclomimetics. The just-out-of-stealth-mode biotech says these drugs will be orally available peptide therapeutics combining the diversity and specificity of antibodies with some of the benefits of small molecules, including oral dosing and longer half-lives. Its first drug program will pursue an oral kallikrein inhibitor for prevention of hereditary angioedema.
You may also be interested in...
Phase II Success Positions Ra For Potential Blockbuster Opportunity In Myasthenia Gravis
Ra hopes to launch a Phase III program for zilucoplan next year, with a goal of bringing an alternative therapy for MG patients into competition with Alexion’s Soliris.
Shire To Test Convenience Versus Familiarity In HAE With Approval Of Firazyr
FDA’s Aug 25 approval of Shire PLC’s Firazyr (icatibant) for acute treatment of attacks of hereditary angioedema, with a label that allows patients to self-administer the drug, puts a convenience advantage up against a first-to-market advantage for the well-established C-1 esterase inhibitors.
Peptide Therapeutics' Rising Tide
As emerging technologies begin to overcome peptide therapeutics’ pharmacologic limitations, their compelling potential grows clearer and their deal value has grown. Most if not all of Big Pharma and Big Biotech now have rebuilt their internal peptide drug development programs and show interest in start-ups with peptide pipelines and platforms.